Equities

Oncology Institute Inc

TOI:NAQ

Oncology Institute Inc

Actions
Health CareHealth Care Providers
  • Price (USD)0.1515
  • Today's Change-0.004 / -2.26%
  • Shares traded5.96m
  • 1 Year change-92.46%
  • Beta0.4940
Data delayed at least 15 minutes, as of Nov 22 2024 17:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects Oncology Institute Inc share price to rise to 2.00 in the next year from the last price of 0.155.
High1,190.3%2.00
Med1,190.3%2.00
Low1,190.3%2.00

Earnings history & estimates in USD

Earnings forecasts are not available for Oncology Institute Inc. On Nov 13, 2024, Oncology Institute Inc reported 3rd quarter 2024 losses of -- per share.
Average growth rate+2.48%
Oncology Institute Inc reported annual 2023 losses of -0.92 per share on Mar 27, 2024.
Average growth rate-206.67%
More ▼

Revenue history & estimates in USD

DFP Healthcare Acquisitions Corp. had 3rd quarter 2024 revenues of 99.90m. This was 31.12% above the prior year's 3rd quarter results.
Average growth rate+5.10%
DFP Healthcare Acquisitions Corp. had revenues for the full year 2023 of 324.24m. This was 28.42% above the prior year's results.
Average growth rate+28.42%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.